What is Vesugen 20MG

Vesugen 20MG is a synthetic tripeptide bioregulator of the Khavinson class studied in research for its highly specific ability to normalize the function of the vascular wall and improve microcirculation. It is intended exclusively for research use.

Regarding its chemical identity, Vesugen has a molecular formula of C14H24N4O7 and a molecular weight of 360.4 g/mol. Its reported canonical sequence is Lys-Glu-Asp. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include Vesugen.

Product for research use.

Mechanism of action of Vesugen

Vesugen interacts directly with the DNA of endothelial cells that line blood vessels. It regulates the synthesis of proteins required for vascular elasticity, reduces endothelial inflammation, and prevents the pathological hardening of arteries under metabolic stress.

Pharmacokinetics and pharmacodynamics of Vesugen

Like other short bioregulators, it features an extremely short biological half-life. The peptide rapidly penetrates the nucleus of endothelial cells, initiates epigenetic repair transcription, and is quickly degraded, leaving long-lasting structural benefits.

Scientific evidence on Vesugen

The available evidence on Vesugen is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Investigated in preclinical models of atherosclerosis, hypertension, and age-related vascular stiffness. Evidence indicates it significantly improves blood flow parameters and accelerates the healing of damaged endothelial linings in laboratory models.

Vesugen applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

Vesugen protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for Vesugen, so no trial schemes or quantities are specified.

The presentations of this product (20MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of Vesugen

As a general guideline for laboratory handling, lyophilized peptides such as Vesugen are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 20MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

Vesugen Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented Vesugen security profile

The documented safety information in open sources for Vesugen is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Targeting the specific epigenetic regulation of blood vessels, it carries a favorable theoretical safety profile. Since it normalizes tissue rather than artificially forcing vasodilation (like nitric oxide donors), it does not typically cause acute hypotensive crises.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

Vesugen in a comparative context

Vesugen is the synthetic analogue of the natural vascular extract Ventfort. While Cardiogen targets the heart muscle itself (myocardium), Vesugen specifically targets the extensive network of blood vessels (endothelium) throughout the entire body.

History and development of Vesugen

Developed by the St. Petersburg Institute of Bioregulation and Gerontology. It was designed to specifically combat the primary cause of cardiovascular mortality: the age-related degradation and stiffening of the vascular endothelial lining.